Your browser doesn't support javascript.
loading
Requirement for YAP1 signaling in myxoid liposarcoma.
Trautmann, Marcel; Cheng, Ya-Yun; Jensen, Patrizia; Azoitei, Ninel; Brunner, Ines; Hüllein, Jennifer; Slabicki, Mikolaj; Isfort, Ilka; Cyra, Magdalene; Berthold, Ruth; Wardelmann, Eva; Huss, Sebastian; Altvater, Bianca; Rossig, Claudia; Hafner, Susanne; Simmet, Thomas; Ståhlberg, Anders; Åman, Pierre; Zenz, Thorsten; Lange, Undine; Kindler, Thomas; Scholl, Claudia; Hartmann, Wolfgang; Fröhling, Stefan.
Affiliation
  • Trautmann M; Gerhard-Domagk-Institute of Pathology, Münster University Hospital, Münster, Germany.
  • Cheng YY; Division of Translational Pathology, Gerhard-Domagk-Institute of Pathology, Münster University Hospital, Münster, Germany.
  • Jensen P; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Azoitei N; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.
  • Brunner I; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Hüllein J; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.
  • Slabicki M; Department of Internal Medicine I, Ulm University Hospital, Ulm, Germany.
  • Isfort I; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Cyra M; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.
  • Berthold R; Department of Translational Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Wardelmann E; Department of Translational Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Huss S; Gerhard-Domagk-Institute of Pathology, Münster University Hospital, Münster, Germany.
  • Altvater B; Division of Translational Pathology, Gerhard-Domagk-Institute of Pathology, Münster University Hospital, Münster, Germany.
  • Rossig C; Gerhard-Domagk-Institute of Pathology, Münster University Hospital, Münster, Germany.
  • Hafner S; Division of Translational Pathology, Gerhard-Domagk-Institute of Pathology, Münster University Hospital, Münster, Germany.
  • Simmet T; Gerhard-Domagk-Institute of Pathology, Münster University Hospital, Münster, Germany.
  • Ståhlberg A; Division of Translational Pathology, Gerhard-Domagk-Institute of Pathology, Münster University Hospital, Münster, Germany.
  • Åman P; Gerhard-Domagk-Institute of Pathology, Münster University Hospital, Münster, Germany.
  • Zenz T; Gerhard-Domagk-Institute of Pathology, Münster University Hospital, Münster, Germany.
  • Lange U; Department of Pediatric Hematology and Oncology, University Children's Hospital Münster, Münster, Germany.
  • Kindler T; Department of Pediatric Hematology and Oncology, University Children's Hospital Münster, Münster, Germany.
  • Scholl C; Cells in Motion Cluster of Excellence, University of Münster, Münster, Germany.
  • Hartmann W; Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm University Hospital, Ulm, Germany.
  • Fröhling S; Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm University Hospital, Ulm, Germany.
EMBO Mol Med ; 11(5)2019 05.
Article in En | MEDLINE | ID: mdl-30898787
ABSTRACT
Myxoid liposarcomas (MLS), malignant tumors of adipocyte origin, are driven by the FUS-DDIT3 fusion gene encoding an aberrant transcription factor. The mechanisms whereby FUS-DDIT3 mediates sarcomagenesis are incompletely understood, and strategies to selectively target MLS cells remain elusive. Here we show, using an unbiased functional genomic approach, that FUS-DDIT3-expressing mesenchymal stem cells and MLS cell lines are dependent on YAP1, a transcriptional co-activator and central effector of the Hippo pathway involved in tissue growth and tumorigenesis, and that increased YAP1 activity is a hallmark of human MLS Mechanistically, FUS-DDIT3 promotes YAP1 expression, nuclear localization, and transcriptional activity and physically associates with YAP1 in the nucleus of MLS cells. Pharmacologic inhibition of YAP1 activity impairs the growth of MLS cells in vitro and in vivo These findings identify overactive YAP1 signaling as unifying feature of MLS development that could represent a novel target for therapeutic intervention.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Transcription Factors / Signal Transduction / Liposarcoma, Myxoid / Adaptor Proteins, Signal Transducing Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: EMBO Mol Med Journal subject: BIOLOGIA MOLECULAR Year: 2019 Document type: Article Affiliation country: Germany

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Transcription Factors / Signal Transduction / Liposarcoma, Myxoid / Adaptor Proteins, Signal Transducing Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: EMBO Mol Med Journal subject: BIOLOGIA MOLECULAR Year: 2019 Document type: Article Affiliation country: Germany